Lee Tzong-Hae, Chafets Daniel M, Reed William, Wen Li, Yang Yunting, Chen Jennifer, Utter Garth H, Owings John T, Busch Michael P
Blood Systems Research Institute, San Francisco, California 94118, USA.
Transfusion. 2006 Nov;46(11):1870-8. doi: 10.1111/j.1537-2995.2006.00992.x.
The characterization of microchimerism (MC) by gene amplification has been limited by few allogeneic markers, ascertainment bias, and assay analytic performance. To address this, a panel of 12 MC assays based on insertion-deletion (InDel) polymorphisms had been optimized.
The InDel assays were validated with comprehensive in vitro spiking studies at the stochastic limit of detection. Their ability was also determined to ascertain MC of unknown source genotype with both theoretical and actual donor-recipient pairs, and the assays were applied to a clinical population of 73 trauma patients who received transfusions where MC was previously characterized by HLA-based assays alone.
In the stochastic spiking experiments, all assays were sensitive to a single copy of target DNA, and no false-positive amplification occurred among 1128 samples studied. Among 219 theoretical donor-recipient pairs, informative alleles existed for 99.5 percent with both InDel and HLA compared to 91.3 percent with HLA alone. In the clinical population, 33 cases of MC were detected (9 more cases than by HLA-DR alone) in the nonleukoreduced (non-LR) group and 8 cases (1 more case than by HLA-DR) in the LR group for the short-term follow-up. Among 27 long-term follow-up samples, 8 cases were detected overall (3 more cases than by HLA-DR alone).
It is concluded that an InDel-based assay panel has excellent technical performance characteristics while also allowing for ascertainment of some MC cases not detectable with HLA alone. The tandem use of both the InDel and the HLA provides a powerful tool for the enhanced ascertainment of MC.
通过基因扩增对微嵌合体(MC)进行特征分析一直受到同种异体标记物较少、确定偏倚和检测分析性能的限制。为了解决这一问题,一组基于插入缺失(InDel)多态性的12种MC检测方法已得到优化。
通过在随机检测限下进行全面的体外加标研究,对InDel检测方法进行了验证。还确定了它们在理论和实际供体-受体对中确定未知来源基因型MC的能力,并将这些检测方法应用于73例接受输血的创伤患者的临床群体,此前该群体中的MC仅通过基于HLA的检测方法进行特征分析。
在随机加标实验中,所有检测方法对单拷贝目标DNA均敏感,在研究的1128个样本中未出现假阳性扩增。在219对理论供体-受体对中,InDel和HLA均存在信息性等位基因的比例为99.5%,而仅HLA存在信息性等位基因的比例为91.3%。在临床群体中,短期随访时,非白细胞滤除(non-LR)组检测到33例MC(比仅通过HLA-DR检测多9例),LR组检测到8例(比通过HLA-DR检测多1例)。在27个长期随访样本中,总共检测到8例(比仅通过HLA-DR检测多3例)。
得出结论,基于InDel的检测方法组具有出色的技术性能特征,同时还能确定一些仅通过HLA无法检测到的MC病例。InDel和HLA的联合使用为增强MC的确定提供了一个强大的工具。